Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Rifaximin (Xifaxan) for Patients With Sickle Cell Disease (SCD)

NCT03719729 is registered in ClinicalTrials.gov with New York Medical College as lead sponsor.

NCT NCT03719729
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03719729 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Rifaximin (Xifaxan) for Patients With Sickle Cell Disease (SCD)
Lead sponsor
New York Medical College
Phase
Phase 2
Overall status
Unknown status
Start date
August 22, 2018
Completion date
July 22, 2020
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

antibiotics, sickle cell disease